The use of preventive medications in people at high risk of cardiovascular disease is conceptually straightforward, yet in practice the adoption of such measures is disappointingly low, plus there is wide international variation in preventive therapies.
Introduction
Global patterns of cardiovascular disease (CVD) are changing, with a fall in coronary mortality and event rates among the higher income countries. In part, this decline is attributable to effective drug measures both in risk factor treatment availability and an improvement in the number of case fatalities. 1 Whilst the burden of CVD has moved to low and lower-middle income countries (LMIC), this transition has not been paralleled by the availability of effective and affordable preventive drugs. There is a mismatch of need and supply, whereby 90% of the world's drugs are distributed to 15% of the world's population. 2 People with established CVD, who are generally those who have suffered and survived a heart attack or a stroke, number in the hundreds of millions worldwide. 3, 4 They represent the highest risk segment of the population, and as thus, are a readily identifiable target for prevention using combination therapy that can address multiple cardiovascular risk factors. However, there is a universal shortfall in preventive medicine coverage even in this group, where there is no contention about the indication for the use of aspirin, statins and blood pressure lowering drugs. This shortfall is most striking in LMIC, but it is also remarkable that even in high income countries, the appropriate treatment coverage is only given to about 50% of those with coronary heart disease and only about 35% of those with stroke. 5 The delivery of proven preventive treatments to patients with CVD should be a high public health priority; however, there are several barriers helping to create important gaps. In low-income settings, issues of availability and affordability are paramount. In many countries, the separate components of such a tablet cocktail are simply not available; while in others, the monthly cost of even a single generic component represents a considerable portion of a month's wages and has the potential to push families further towards poverty. 6, 7 The high cost of treatment can lead to lost employment opportunities, as well as lost economic and social opportunities for young adults and women in particular. In all populations, irrespective of income level, dose complexity and pill burden confer major difficulties. A pill burden of six or more pills per day is not uncommon, especially with co-morbid problems, such as diabetes, present. It is known that the number of pills prescribed is inversely related to adherence and that low adherence negates prevention. 8, 9 A combination pill taken once daily, a cardiovascular 'polypill' cocktail based on a combination of established generic drugs, may be able to address these issues. 10 In 2009, the European Commission called for improved treatment of chronic diseases in developing countries. Specifically, they invited a treatment strategy 'that combines existing safe and effective drugs for treating chronic diseases in a single daily pill,' stipulating that 'this fixed-dose-combination pill should be lowcost and suitable for production and widespread use in resource-poor countries' and that the work should 'address two major challenges of effective secondary prevention and treatment of chronic diseases: adherence to treatment and access to treatment in developing countries.' The importance of these questions was also voiced by the US Centers for Disease Control and Prevention (CDC). The UMPIRE (i.e. Use of a Multidrug Pill In Reducing cardiovascular Events) trial was designed in response to this call. UMPIRE is part of a wider collaboration, the SPACE (i.e. 'Single Pill to Avert Cardiovascular Events,' http:// www.spacecollaboration.org/) group, which runs parallel trials with very similar protocols: the 'IMProving Adherence using Combination Therapy' 11 (IMPACT) and 'Kanyini Guidelines Adherence with the Polypill' 12 (Kanyini-GAP) in New Zealand and Australia, respectively
Methods

Study design
The UMPIRE trial is a prospective, randomised, open label, blinded endpoint (PROBE) clinical trial of a polypill-based treatment strategy, as compared to usual care, in participants at high cardiovascular risk. Participants are randomised to continue with usual care or to a polypill-based treatment strategy and then followed until at least 12 months after the last participant has been included ( Figure 1 ). The trial had investigator sites located in India (with coordinating centres in Delhi and Hyderabad) and in three countries in Europe (England, Ireland and The Netherlands), but all sites were managed by a central coordinating office in London, UK.
Study objectives
1. The primary objective was to assess whether provision of a polypill-based cardiovascular preventive treatment strategy, as compared to any usual medications, improves adherence to the indicated therapy and whether it induces changes in two major cardiovascular risk factors (blood pressure and LDL-cholesterol) in people at high risk of cardiovascular events.
2. Secondary objectives were: assessing barriers to adherence, quality of life, safety, cardiovascular events and comparison of results between the participating countries. Economic and process evaluations of the polypill strategy are planned. Protocols for the latter two objectives are described separately.
Subjects
This trial was designed to include 2000 participants who had either a history of atherothrombotic CVD or a calculated 5-year CVD risk of !15%. Inclusion criteria:
. Aged !18 yrs and able to give informed consent;
. High cardiovascular risk, defined as either:
. established atherothrombotic CVD, defined as: A history of coronary heart disease (myocardial infarction, stable or unstable angina pectoris, or coronary revascularisation procedure); or A history of ischaemic cerebrovascular disease (ischaemic stroke or transient ischaemic attack); or A history of peripheral vascular disease (peripheral revascularisation procedure or amputation due to vascular disease); or . a 5-year risk of !15% (calculated using the Framingham risk equation as adjusted by the New Zealand Guidelines Group 13, 14 ) ;
. The trial physician considers that each of the polypill components are indicated at the doses in the polypill.
Exclusion criteria were one or more of the following:
. Contraindication to or known intolerance of any of the components of the polypill; . The trial physician considers that changing a participant's cardiovascular medications would put the participant at risk (e.g. symptomatic heart failure, severe renal insufficiency, a history of resistant hypertension); . A known situation where medication might be altered for a significant length of time (e.g. planned surgery); . Unlikely to complete the trial, adhere to the trial procedures or attend study visits.
The number of trial sites in each country reflected their respective health systems. The three participating European research units were linked to established clinical research networks and disease registries covering wide catchment areas in small countries. Recruitment in the European centres thus benefited from infrastructures that were previously established to facilitate research participation originating from both general practice and hospital clinics. In the absence of disease registries in India, it was expedient to include numerous hospitals that reflected patient groups across the country, so 28 centres were identified at secondary and tertiary teaching and non-teaching hospitals, from different parts of India. Each site had a participant target of n $ 35. Participants were recruited by the physicians running clinics for post-myocardial infarct or poststroke patients (see apcknowledgements for full list of trial sites). Recruitment was completed between June 2010 and July 2011, with the inclusion of n ¼ 2004 participants (1000 in India; 1004 in Europe). Table 1 describes the baseline characteristics of the trial participants and illustrates that the majority were included on the basis of having established CVD. Overall, 28% of the participants had diabetes (33% of the Indian participants and 23% of the Europeans).
Randomisation
Randomisation was conducted 1 : 1 for assigning polypill versus usual care, using a centralised, web-based electronic data capture system (InForm). The allocation sequence was stratified by site and by the presence or absence of established CVD.
Study treatment
Participants who were randomised to usual care continued to be treated at the discretion of their routine treating doctor, in a manner consistent with current guideline-indicated cardiovascular medications. Beyond giving advice to follow current CVD prevention guidelines, no attempt was made to influence the format of 'usual care.' Participants who were randomised to the polypill strategy were prescribed one of two polypill formulations, at the discretion of the trial investigator: Red Heart Pill (RHP) version 1 or RHP version 2. The contents of these two polypills are listed in Table 2 . The polypill was taken orally, once daily with the dose timing left to the discretion of both the physician and the participant. RHP version 1 may be deemed most suitable for patients with coronary heart disease, while RHP version 2 could be found most suitable for patients with cerebrovascular disease, with peripheral vascular disease or those without established CVD. Within this context, the polypill is regarded as 'background treatment' to which additional medications can be added, according to each individual's requirements to achieve a target blood pressure or cholesterol level, or to treat concomitant conditions. Participants in the polypill group were dispensed the RHP free of any charge from their trial centre. Participants in the usual care group acquired their medications subject to the prevailing local payments or exemptions.
The RHP that was used in this trial was manufactured and provided without cost by Dr. Reddy's Laboratories (Hyderabad, India) to all three of the current trials within the SPACE collaboration.
Follow-up
After the recruitment interval of 12.5 months, participants will be followed for a minimum of 1 year (one year after the last participant was randomised). Average follow-up is anticipated to be about 15 months. The follow-up schedule and data to be collected at each visit are illustrated in Table 3 . Participants attended clinic visits for randomisation, as well as at 12 months and the end of the study. Telephone or clinic visits were conducted at: 1 month, 6 months and 18 months (if applicable). All other interim visits to the participants' routine treating doctors were to occur as usual. Blood pressure and fasting lipids were measured at baseline, as well as at 12 months and the end of the trial. Blood pressure and heart rate measurements were standardised according to British Hypertension Society guidelines, using automated electronic devices (Omron 705CP II) provided to each of the research centres. Fasting blood samples were to be analysed by the local laboratory linked with each trial centre. Self-reported adherence to all medications was assessed at all trial visits and recorded as the number of days that medication was taken in the week prior to a trial visit (thus a value between 0-7 days). During trial contacts, the research team also asked about any barriers to adherence, quality of life, any cardiovascular and other serious adverse events, and any reasons for stopping cardiovascular medications. The reporting of adverse events was restricted to serious adverse events, due to the open-label nature of the trial and the polypill components already having wellknown safety and efficacy profiles. The Data and Safety Monitoring Board would convene on a 6-month basis, to assess trial safety and outcome data. The research team was to contact the usual treating doctor at the end of the trial, to evaluate the acceptability of the prescribing strategy (for polypill patients). The low intensity of follow-up minimises the likelihood of any external influence on adherence, particularly minimising the potential influence by the investigators.
Outcomes
Primary outcomes:
1. Adherence to indicated medications (defined as selfreported current use of antiplatelet, any statin and a combination (!2) blood pressure lowering therapy) at the end of the trial. Current use of a medication will be defined as taking the medication for at least 4 days during the week preceding the study-related visit.
A change in systolic blood pressure from baseline to
the end of the trial. 3. A change in LDL-cholesterol from the baseline measurement to the end of the trial.
Secondary outcomes:
a. Self-reported current use of antiplatelet, statin and combination (!2) blood pressure lowering therapy at 12 months; b. dispensing of statin and !2 types of blood pressure lowering agents over the course of the trial; c. reasons for stopping cardiovascular medications (all visits); d. serious adverse events (between baseline and 28 days after the end of trial visit); e. quality of life (baseline, 12 months and end of trial); f. changes in diastolic blood pressure, total cholesterol and other lipid fractions (HDL-cholesterol, triglycerides) and creatinine, from baseline through 12 months, and the end of the follow-up period; g. cardiovascular events, defined as:
. all coronary heart disease events including death from CHD, otherwise unexplained sudden death, 
Sample size
Randomisation of 1000 participants to the European component of the trial, and another 1000 to the Indian component, will provide 90% power at a 2-sided 0.05 significance level in each component to enable detection of at least a 3 mmHg difference in systolic blood pressure, 0.20 mmol/L difference in cholesterol and a 10% absolute difference in treatment adherence rates between the intervention and control groups, at the end of the trial. This will allow for 10% deaths, withdrawals and/ or loss to follow-up; current data indicate that this is a conservative assumption. The trial will have the power to assess consistency between major subgroups, which are defined by factors such as location, age and sex. These estimates assume standard deviations around the change from baseline of 0.8 mmol/L and 14 mmHg, in LDL-cholesterol and blood pressure respectively, and intention-to-treat analyses.
Study management and registration
The UMPIRE trial was sponsored by the Imperial College of London and funded by a grant from the European Commission. The central coordinating office for this study is located at the International Centre for Circulatory Health (ICCH), in the Imperial College of London. The following committees were put in place:
. Steering;
. Project Management Team;
. Data and Safety Monitoring Board;
. Expert Advisory Board;
. Clinical Endpoint Adjudication.
Local management of the Indian Investigator sites was the responsibility of the two coordinating teams within India (located at the Centre for Chronic Disease Control, New Delhi, and The George Institute for Global Health, Hyderabad) whom were tasked with supervising 28 sites across the country (Figure 2 and see list of collaborators in the acknowledgments). The three trial centres in Europe were located at: the Royal College of Surgeons in Dublin, Ireland; the Julius Center, University Medical Center Utrecht, the Netherlands; and the ICCH at the Imperial College of London, UK; which were all managed by the team at ICCH. Monitoring teams in London and India were directed by the global project manager, to ensure full compliance with the protocol, good clinical practice, ethics and regulatory requirements. 
Ethics review
Ethics approval was granted by the independent ethics committees in each participating country. For example, in India, the protocol was submitted via the Indian Council for Medical Research for approval by the Health Ministry's Screening Committee, and it was subsequently favourably reviewed by the ethics boards that were relevant to each trial site.
Discussion
A high proportion of all cardiovascular events occur in those persons with established disease. 5, 15, 16 Preventive treatment in this group has the potential to reduce the risk of further myocardial infarction or stroke by 50% or more. 17, 18 The use of these drugs is advocated in this context in European and Indian national guidelines; in fact aspirin, statins, beta-blockers and ACE-inhibitors are all on the WHO list of essential medicines, 19 yet the uptake of preventive practice with them and rates of continuation of this strategy in all regions of the world is currently disappointingly low. 5 The reasons for the treatment gaps differ between countries, with an important influence provided by their differing healthcare systems and economies, but common considerations do include both the complexity and cost of the treatment package and its delivery mechanism.
Adherence to chronic disease treatment regimens diminishes as the number of drugs in the regimen increases. Reduced adherence does relate to increased cardiovascular risks. 20 Furthermore, several studies indicate that there is improved adherence for a fixed combination dosage, when compared to taking individual single drugs. 21, 22 A recent intervention study in the US shows an important improvement in adherence that is solely related to complete elimination of medication costs. 23 In LMIC such as India, medication costs are normally paid out of pocket, 2,24 so it is easy to recognise how high drug costs in LMICs make most preventive strategies for chronic diseases prohibitively expensive, yet >80% of the world's CVD deaths do currently occur in these countries. A 'call to action' has urged the pharmaceutical industry to 'ensure the availability, affordability, and accessibility of low-cost generic drugs for the management of people at high risk of chronic diseases, especially CVD.' [25] [26] [27] Many contend that CVD prevention effort should focus on healthy lifestyle measures, 28, 29 and although this is undoubtedly true, concurrently we have very effective drugs that could avert, or at least defer, a very large proportion of the final consequences of CVD, even if applied late. These low-cost drugs need to be incorporated into a complementary, global preventive approach. 30 The drugs might best be provided as a polypill, but there is an important outstanding question: 'Will patients and healthcare providers adopt such a strategy; will they really use a polypill?' The UMPIRE trial addresses this question.
The trial is testing the impact of a polypill-based treatment strategy on adherence, in comparison with usual care in as realistic a setting as possible, within the constraints of a clinical trial. The self-reported adherence endpoint is objectively evaluated by measurements of within-trial changes in blood pressure and cholesterol. The trial has recruited on schedule. The participants' baseline characteristics are much as expected in a cohort with recognised and treated cardiovascular risk factors. The younger age of the participants in India (Figure 3 ) is in keeping with the observation that CVD afflicts people at a younger age in LMIC.
In Australia and New Zealand, the investigators of the Kanyini-GAP and IMPACT trials have been able to place the prescribing and dispensing of the RHP into community general practice and community pharmacies, respectively. This ideal construct very closely reflects the real world, but regulations in India and in the three European countries in our study prohibit distribution of a trial treatment by any other than the approved trial teams, and also prohibit charging for the prescription of trial treatments. Consequently, UMPIRE participants who were allocated to the polypill group received their medication free of charge from the trial centres, but the participants allocated to usual care received their medications via their routine clinic or general practitioner attendance. This presents a potential bias favouring the polypill strategy; however, this would indeed reflect the real impact if the treatment were to be made available later at low or no cost to the end-user, e.g. following bulk purchases. On the other hand, there is the potential for a 'Hawthorn effect' favouring the control group in this trial; because as treatment is unblinded, the physicians may, consciously or otherwise, improve the levels of 'usual care.' The necessity of having an unblinded design might entail differential patient-healthcare encounters between the two groups; however, the low-intensity follow-up schedule ( Table 3 ) militates against this, plus supplies of RHP are given to the relevant participants in sufficient quantity that could last up to 6 months. Data about additional medical encounters (outside the protocol) were collected during the course of the trial and were also examined in the process evaluation.
The SPACE collaboration will provide an opportunity to assess the consistency or lack thereof of the primary outcomes across even more diverse geographic healthcare settings. In addition, the individual patient data meta-analysis will have the most power to assess non-inferiority, when compared to usual care; for example, if no statistical difference is shown overall, can polypill-based care be reliably regarded as being non-inferior to usual care, according to certain pre-specified margins.
The polypill is a repackaging of effective preventive drugs into a combination pill: all of the groups outlining the potential of such an intervention have so far noted that it is not a panacea for CVD and it does not displace the importance of measures of lifestyle change such as not smoking, increasing healthy nutrition and regular exercise. 17, 18, 31 These approaches are complementary. The major challenge lies in defining and implementing the most effective delivery strategy. If adopted, a preventive polypill has the potential to bring effective CVD prevention within economic reach of individuals and governments of poorer countries. This is now of particular priority in LMICs, where 80% of the cardiovascular burden lies, yet the vast majority of individuals currently receive little or no long-term medical preventive care and, even when even available, it often remains unaffordable. 32 
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